Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07SQT
|
|||
| Former ID |
DNCL002318
|
|||
| Drug Name |
Ferroportin mab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Phase 1 | [1] | |
| Company |
Eli Lilly
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Solute carrier family 40 member 1 (SLC40A1) | Target Info | . | [2] |
| KEGG Pathway | Mineral absorption | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Reactome | Iron uptake and transport | |||
| WikiPathways | Iron uptake and transport | |||
| Iron metabolism in placenta | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01991483) A Study of LY2928057 in Hemodialysis Participants. U.S. National Institutes of Health. | |||
| REF 2 | The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 March; 35(3): 155-161. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.